|
| Trial | Phase | Drug | Key result |
|
| IMpassion130 [25] | 3 | Nab-paclitaxel + atezolizumab | PFS: 7.2 vs 5.5 mo HR = 0.80 (0.69–0.92) |
| Nab-paclitaxel + placebo | OS: 21.0 vs 18.7 mo HR = 0.87 (0.725–1.02) |
| | PD-L1+: OS 25.4 vs 19.7 mo HR = 0.69 (0.54–0.88) |
| | PFS: 7.5 vs 5.3 mo HR = 0.63 (0.50–0.80) |
|
| IMpassion131 [26] | 3 | Paclitaxel + atezolizumab | ITT: PFS: 5.7 vs 5.6 mo HR = 0.86 |
| Paclitaxel + placebo | (0.70–1.05) OS: 19.2 vs 22.8 mo |
| | HR = 1.12 (0.88–1.43) |
| | PD-L1+: PFS: 6.0 vs 5.7 mo |
| | HR = 0.82 (0.60–1.12) |
| | OS: 22.1 vs 28.3 mo HR = 1.11 (0.76–1.64) |
|
| KEYNOTE-119 [23] | 3 | Pembrolizumab | OS: 9.9 vs 10.8 mo HR = 0.97 (0.82–1.15) |
| Physician’s chemotherapy choice | PFS: 2.1 vs 3.3 mo HR = 1.60 (1.33–1.92) |
| | CPS >10: OS: 12.7 vs 11.6 mo HR = 0.78 (0.57–1.06) |
| | PFS: 2.1 vs 4.3 mo HR = 1.14 (0.82–1.59) |
|
| KEYNOTE-355 [27] | 3 | Nab-paclitaxel/paclitaxel/gemcitabine/carboplatin + pembrolizumab | PFS: 7.5 vs 5.6 mo HR = 0.82 (0.69–0.97) |
| | CPS ≥10: PFS: 9.7 vs 5.6 mo HR = 0.66 (0.50–0.88) |
| | OS: 23 vs 16.1 mo HR = 0.73 (0.55–0.95) |
| | CPS ≥1: PFS: 7.6 vs 5.6 mo HR = 0.75 (0.62–0.91) |
|
| KEYNOTE-522 [28] | 3 | Carboplatin + paclitaxel + 4xAC + pembrolizumab ->pembrolizumab in adjuvant | pCR: 64.8 vs 51.2%
PD-L1+: pCR 68.9 vs 54.9% events: 15.7 vs 23.8% |
| Carboplatin + paclitaxel + 4xAC + placebo -> placebo in adjuvant | HR = 0.63 (0.48–0.82) |
|
